Osteoporosis treatment discontinued

Protelos (strontium ranelate) has been withdrawn worldwide for commercial reasons.

Further information

Manufacturer: Servier

The drug was licensed to treat severe osteoporosis in postmenopausal women and adult men at high risk of fracture for whom other osteoporosis treatments were unsuitable (eg, because of contraindications or intolerance).

The manufacturer of Protelos, Servier, decided to withdraw the drug after its indications were restricted over cardiovascular concerns and the number of patients treated with the drug declined.

Servier has been liaising with the relevant patient and professional organisations, such as the National Osteoporosis Society, the British Society of Rheumatology and the Primary Care Rheumatology Society, to make them aware of the discontinuation.

GPs are advised to identify and review any patients who are currently prescribed strontium ranelate and discuss alternative treatment options with them. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Learn about neurological aspects of 'long COVID’ at a MIMS Learning webinar

Learn about neurological aspects of 'long COVID’ at a MIMS Learning webinar

Loss of taste and smell and neurological aspects of...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

First triple combination MDI licensed for asthma

First triple combination MDI licensed for asthma

Trimbow (beclometasone/formoterol/glycopyrronium) can...